PROCEPT BioRobotics (PRCT) to Release Earnings on Tuesday

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) will likely be releasing its earnings data after the market closes on Tuesday, February 25th. Analysts expect PROCEPT BioRobotics to post earnings of ($0.34) per share and revenue of $66.79 million for the quarter. Individual that wish to register for the company's earnings conference call can do so using this link.

PROCEPT BioRobotics Stock Performance

NASDAQ:PRCT traded down $3.14 during mid-day trading on Friday, reaching $62.25. 1,465,542 shares of the stock were exchanged, compared to its average volume of 861,542. The stock has a market capitalization of $3.25 billion, a P/E ratio of -31.92 and a beta of 1.03. PROCEPT BioRobotics has a 1 year low of $45.20 and a 1 year high of $103.81. The company has a 50 day simple moving average of $76.53 and a 200-day simple moving average of $79.72. The company has a quick ratio of 5.07, a current ratio of 6.02 and a debt-to-equity ratio of 0.21.

Analysts Set New Price Targets

PRCT has been the topic of a number of research reports. Morgan Stanley initiated coverage on shares of PROCEPT BioRobotics in a research report on Monday, December 2nd. They set an "overweight" rating and a $105.00 target price on the stock. Wells Fargo & Company reissued an "overweight" rating and set a $112.00 price objective on shares of PROCEPT BioRobotics in a research report on Tuesday, December 3rd. Jefferies Financial Group initiated coverage on shares of PROCEPT BioRobotics in a report on Thursday, November 14th. They issued a "hold" rating and a $95.00 target price for the company. Finally, Truist Financial reissued a "buy" rating and set a $105.00 price target (up previously from $95.00) on shares of PROCEPT BioRobotics in a report on Wednesday, October 30th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $97.86.

Insider Transactions at PROCEPT BioRobotics

In other news, EVP Alaleh Nouri sold 28,092 shares of the stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $97.13, for a total transaction of $2,728,575.96. Following the completion of the transaction, the executive vice president now directly owns 52,472 shares of the company's stock, valued at approximately $5,096,605.36. This represents a 34.87 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Reza Zadno sold 26,420 shares of PROCEPT BioRobotics stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $97.83, for a total value of $2,584,668.60. Following the completion of the sale, the chief executive officer now owns 179,185 shares in the company, valued at approximately $17,529,668.55. This trade represents a 12.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 80,935 shares of company stock worth $7,882,089. Company insiders own 17.40% of the company's stock.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).